Hospira has previously responded to FDA warning letters with facility improvements and corrective action plans that met regulatory requirements
That translates to tens of millions of people worldwide living with a condition that is only partially understood, frequently dismissed in conventional medical settings, and for which there is currently no FDA-approved treatment

redrag Sikiri, Sven Seiwerth, eljko Grabarevi, Rudolf Ruman, Marijan Petek, Vjekoslav Jagi, Branko Turkovi, Ivo Rotkvi, Stjepan Mie, Ivan Zorii, Pako Konjevoda, Darko Perovi, Ljubica Jurina, Jadranka eparovi, Miro Hanevaki, Branka Artukovi, Mirna Bratuli, Marina Tiljar, Miro Gjurain, Pavao Mikli, Dinko Stani-Rokotov, Zoran Slobodnjak, Nikola Jelovac, Anton Marovi, The influence of a novel pentadecapeptide, BPC 157, on NG-nitro-l-arginine methylester and l-arginine effects on stomach mucosa integrity and blood pressure, European Journal of Pharmacology, Volume 332, Issue 1, 1997, Pages 23-33, ISSN 0014-2999, Seiwerth S, Rucman R, Turkovic B, Sever M, Klicek R, Radic B, Drmic D, Stupnisek M, Misic M, Vuletic LB, Pavlov KH, Barisic I, Kokot A, Japjec M, Blagaic AB, Tvrdeic A, Rokotov DS, Vrcic H, Staresinic M, Sebecic B, Sikiric P
Ellis JA, Ponsonby AL, Pezic A, Williamson E, Cochrane JA, Dickinson JL, et al
There is no universal recommendation, and the choice should ideally be guided by clinical assessment and, where appropriate, laboratory testing